Isupetasys (007660) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Isupetasys stock KRW 24,431, price KRW 62,100, that is 60.7% below the price, quality 49 out of 100. Rating: strongly overvalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 2, 2026.
How to read this chart
60‑month range 4,275 KRW – 161,400 KRW · fair‑value band 13,003 KRW – 40,788 KRW · the 62,100 KRW price screens above the 24,431 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 2, 2026.
Follow Isupetasys in your weekly email
Every Wednesday you see whether Isupetasys is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ISU Petasys Co., Ltd. manufactures and sells printed circuit boards (PCBs). The company offers network equipment, including router/switch and backplane; server/storage PCB; supercomputer high-performance computing PCB; aerospace PCB; and IC testers, including probe card, load board, and burn-in board.
Show moreShow less
It also provides advanced driver assistance system RF radar PCBs; and radio frequency (RF) PCBs. The company was formerly known as Petasys Co., Ltd. and changed its name to ISU Petasys Co., Ltd. in March 2002. ISU Petasys Co., Ltd. was founded in 1972 and is headquartered in Daegu, South Korea.
Stock analysis
Isupetasys (007660) currently trades at 62,100 KRW, while our model-based Fair Value estimate is 24,431 KRW, 61% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 56,220 KRW per share, and 1 of the 25 models we run sit above the 62,100 KRW price.
Bear case: the Asset-Based group reads lowest at 4,478 KRW, and 24 of the 25 models stay below the price. Data coverage for this calculation is high.
Scenario range: 13,003 KRW (bear) to 40,788 KRW (bull), the price of 62,100 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Technology sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Isupetasys reported revenue of 1.1T KRW in FY2025 versus 470B KRW in FY2021, a compound +23.4%/yr. Reported net income was 160B KRW in FY2025.
Key figures
Market cap 4.7T KRW (≈ $3.5B) Mid · P/E ratio 35.0 · P/S ratio 3.60 · EPS (TTM) 2,738 KRW · Dividend yield 0.4% · Net margin 15.3% · Return on equity 26.4% · Return on assets (EBIT) 14.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 73 out of 100 (low confidence).
What moves the price
The share trades about 62% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Technology peers we cover trades at −7% fair-value upside, at −61%, 007660 screens richer than that median.
Fair Value models
Bear13,003 KRWFair Value 24,431 KRWBull40,788 KRW
Price 62,100 KRW · Downside -60.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (2,143 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF3,316 KRW4,428 KRW5,881 KRW81
Growth DCF3,302 KRW4,312 KRW5,561 KRW80
Residual Income10,961 KRW13,999 KRW20,715 KRW75
All 25 models by family
DCF Models
FCF DCF3,316 KRW4,428 KRW5,881 KRW81
5Y Revenue Exit15,721 KRW28,742 KRW46,132 KRW71
5Y EBITDA Exit23,796 KRW44,347 KRW69,347 KRW73
5Y P/E Exit25,180 KRW47,020 KRW70,949 KRW69
10Y Revenue Exit9,514 KRW18,823 KRW32,477 KRW64
10Y EBITDA Exit14,537 KRW28,192 KRW47,986 KRW66
10Y P/E Exit15,297 KRW29,797 KRW49,056 KRW62
Earnings-Based
Graham-Dodd14,866 KRW54,208 KRW73,147 KRW64
Lynch FV12,900 KRW18,429 KRW23,958 KRW61
PEG = 1.012,900 KRW18,429 KRW23,958 KRW57
EPV18,641 KRW20,752 KRW22,462 KRW74
Dividend Discount
Gordon GGM891.57 KRW1,485 KRW1,919 KRW68
DDM Multi-Stage891.57 KRW1,412 KRW1,598 KRW67
Multiples
P/E Multiple45,909 KRW61,212 KRW76,514 KRW63
P/S Multiple27,873 KRW37,164 KRW46,455 KRW58
P/B Multiple41,889 KRW55,852 KRW69,816 KRW55
EV/EBIT49,318 KRW66,085 KRW82,852 KRW66
EV/EBITDA42,195 KRW56,588 KRW70,981 KRW67
EV/Revenue24,446 KRW35,345 KRW46,244 KRW53
Asset-Based
NCAV (Graham)2,956 KRW4,478 KRW5,598 KRW54
Growth DCF
Growth DCF3,302 KRW4,312 KRW5,561 KRW80
Rev-Margin DCF15,721 KRW28,270 KRW43,186 KRW71
Economic Profit
Residual Income10,961 KRW13,999 KRW20,715 KRW75
ROIC Compounder19,815 KRW23,572 KRW27,648 KRW72
Growth Earnings
Growth-Adj P/E29,317 KRW41,882 KRW54,446 KRW67
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+30.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.2%
Start year 2020 (pandemic). Over 10 years: +7.6% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+29.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+29.2%
Dividend (yield on the price)0.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 19%
2025 sits 92% above its own trend. The rate follows the median trend of the last 3 years, not that single year.
⚠ Revenue per share shrinking 1.1%/yr over ~7Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+79.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+38.9%
Yearly sales growth analysts expect, extended to five years.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +75.8% a year for the price and +36.0% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Electronic Components · 651 stocks
Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score49 · Below median
Fair Value upside−60.7% · Below median
Profitability
Return on equity (12 months)26.4% · Top 25%
Return on assets12.5% · Top 25%
Net margin (12 months)15.3% · Top 25%
Operating margin (12 months)20.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)57.4% · Top 25%
Dividend yield (12 months)0.4% · Bottom 25%
Balance sheet
Debt / equity0.13× · Above median
Valuation Multiplesvs Electronic Components median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Isupetasys Fair Value". https://www.fairvalue-calculator.com/stock/007660
Frequently asked questions
Is Isupetasys (007660) overvalued or undervalued?
As of Nov 2, 2026, our model estimates a fair value of 24,431 KRW versus a price of 62,100 KRW, about 61% lower (overvalued).
What is the fair value of 007660?
Our model-based fair value for Isupetasys is 24,431 KRW (as of Nov 2, 2026), built from audited fundamentals. The current price: 62,100 KRW.
What is the quality score of 007660?
Isupetasys has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Isupetasys (007660)?
Our model-based price target is the fair value of 24,431 KRW (as of Nov 2, 2026) from 25 valuation models. Cautious scenario 13,003 KRW, optimistic scenario 40,788 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Isupetasys stock forecast for 2026?
Our models put fair value at 24,431 KRW, about 61% lower versus a price of 62,100 KRW (overvalued). Cautious scenario 13,003 KRW, optimistic scenario 40,788 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Isupetasys (007660)?
Isupetasys reported trailing-twelve-month revenue of about 1.3T KRW (latest available figure, as of Nov 2, 2026).
Does Isupetasys pay a dividend?
Isupetasys currently shows a dividend yield of 0.37% relative to its recent price (as of Nov 2, 2026).
How much is the dividend of Isupetasys (007660) and when is the ex-dividend date?
Isupetasys pays a dividend of 230.00 KRW per share a year, a dividend yield of 0.4%. The last ex-dividend date was Mar 30, 2026. The payout ratio is 8.4% of earnings. Free cash flow covers the dividend 0.81 times. Our assessment: Token dividend. At a yield of 0.4% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.4% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What growth is priced into Isupetasys (007660)?
For today's price to be fair in a discounted-cash-flow model, Isupetasys would have to grow free cash flow by +79.5 % per year for five years (discount rate 12.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.2 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 2, 2026.
What discount rate (WACC) does the fair value of 007660 use?
Our models discount Isupetasys at 12.6 %: a base by market capitalisation (mid), damped by beta 2.02, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Isupetasys that is +79.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.6 %) and the same formula as our fair value.
How much growth has Isupetasys (007660) delivered so far?
Over the past 5 years revenue at Isupetasys grew +16.2 % a year. The price currently implies free-cash-flow growth of +79.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Isupetasys (007660) growing?
The median revenue growth in the sector is +11.5 % a year. That is the yardstick for the growth priced into Isupetasys (+79.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Isupetasys (007660)?
The free-cash-flow yield on the price is 0.30 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Isupetasys produces per unit of market value. When it exceeds the discount rate of our models (12.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Isupetasys (007660)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Isupetasys it is 24,431 KRW per share (as of Nov 2, 2026), against a price of 62,100 KRW. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Isupetasys stock overvalued or undervalued in 2026?
As of Nov 2, 2026, 007660 trades above its calculated fair value: price 62,100 KRW, fair value 24,431 KRW, a gap of about −61% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 007660?
No. The price is what the market pays today (62,100 KRW); the fair value is what the company's own numbers justify (24,431 KRW). For Isupetasys the two are 37,669 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Isupetasys worth?
The market values Isupetasys at about 4.7T KRW (market capitalisation, as of Nov 2, 2026). Per share that is 62,100 KRW; our models calculate a fair value of 24,431 KRW per share.
What do the bullish and bearish scenarios say about 007660?
Our models span a range for Isupetasys: cautious scenario 13,003 KRW, base 24,431 KRW, optimistic 40,788 KRW per share (as of Nov 2, 2026, price 62,100 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 007660?
Isupetasys trades at a price-to-earnings ratio of 35.0 (as of Nov 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 24,431 KRW is built from several models across several years. Other multiples: P/B 6.3, P/S 3.6, EV/EBITDA 15.8.
How solid is the balance sheet of Isupetasys (007660)?
Balance-sheet figures for Isupetasys (as of Nov 2, 2026): return on equity 26.4%, debt of 0.13 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 007660 from its 52-week high?
Isupetasys trades at 62,100 KRW, about 62% below its 52-week high of 161,400 KRW and 5% above the low of 59,200 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 24,431 KRW is for.
Which stocks are comparable to Isupetasys?
From the same area (Technology) we also value Amphenol Corporation, Hon Hai Precision Industry Co, Corning Incorporated, Delta Electronics, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Isupetasys stock attractive at the current price?
The data as of Nov 2, 2026: price 62,100 KRW, calculated fair value 24,431 KRW (−61%), Quality Score 49/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 007660 calculated?
We run Isupetasys through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 24,431 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Isupetasys itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Isupetasys (007660)?
The closing price on Nov 6, 2026 was 62,100 KRW. Our model-based fair value is 24,431 KRW, about 61% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Isupetasys right now?
The price sits above even our optimistic bull case (40,788 KRW). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (13,003 KRW to 40,788 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of Isupetasys
How large is the market capitalisation of Isupetasys (007660)?
The market capitalisation of Isupetasys is 4.7T KRW (≈ $3.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Isupetasys (007660)?
The price-to-sales ratio of Isupetasys is 3.60 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Isupetasys (007660)?
Earnings per share at Isupetasys are 2,738 KRW (price ÷ EPS = P/E 35.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Isupetasys (007660)?
The dividend yield of Isupetasys is 0.4% (payout 8.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Isupetasys (007660)?
The net margin of Isupetasys is 15.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Isupetasys (007660)?
The return on equity (ROE) of Isupetasys is 26.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Isupetasys (007660)?
On an EBIT basis the return on assets of Isupetasys is 14.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Isupetasys (007660)?
The operating margin of Isupetasys is 20.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Isupetasys (007660)?
Revenue at Isupetasys is growing +57.4% versus a year earlier (3y avg +19.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Isupetasys (007660)?
Earnings per share at Isupetasys are growing +85.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Isupetasys (007660) carry?
The net debt of Isupetasys is 72.2B KRW (fiscal year 2025, ≈ 5.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Isupetasys in the live analysis
One click puts Isupetasys on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 2, 2026